Adaptive therapy of human cancers: targeting cancer evolution

Abstract

Zhang Dandan, Yue Hongyun, Zhang Baihong. Adaptive therapy of human cancers: targeting cancer evolution[J]. Journal of International Oncology, 2020, 47(6): 368-371.

References39

[1]	Baez-Ortega A, Gori K, Strakova A, et al. Somatic evolution and global expansion of an ancient transmissible cancer lineage[J]. Science, 2019, 365(6452). pii: eaau9923. DOI: 10.1126/science.aau9923. doi:10.1126/science.aay3158pmid:31371598
[2]	Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor evolution as a therapeutic target[J]. Cancer Discov, 2017. DOI: 10.1158/2159-8290.CD-17-0343. doi:10.1158/2159-8290.CD-20-0495pmid:32611733
[3]	Cui R, Medeiros T, Willemsen D, et al. Relaxed selection limits lifespan by increasing mutation load[J]. Cell, 2019, 178(2):385-399.e20. DOI: 10.1016/j.cell.2019.06.004. doi:10.1016/j.cell.2019.06.004pmid:31257025
[4]	Bakhoum SF, Landau DA. Cancer evolution: no room for negative selection[J]. Cell, 2017,171(5):987-989. DOI: 10.1016/j.cell.2017.10.039. doi:10.1016/j.cell.2017.10.039pmid:29149612
[5]	Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer[J]. Nat Rev Genet, 2019,20(7):404-416. DOI: 10.1038/s41576-019-0114-6. doi:10.1038/s41576-019-0114-6pmid:30918367
[6]	Ujvari B, Papenfuss AT, Belov K. Transmissible cancers in an evolutionary context[J]. Bioessays, 2016,38(Suppl 1):S14-S23. DOI: 10.1002/bies.201670904. doi:10.1002/bies.201670904
[7]	Cannataro VL, Townsend JP. Neutral theory and the somatic evolution of cancer[J]. Mol Biol Evol, 2018,35(6):1308-1315. DOI: 10.1093/molbev/msy079. doi:10.1093/molbev/msy079pmid:29684198
[8]	Persi E, Wolf YI, Leiserson MDM, et al. Criticality in tumor evolution and clinical outcome[J]. Proc Natl Acad Sci U S A, 2018,115(47):E11101-E11110. DOI: 10.1073/pnas.1807256115. doi:10.1073/pnas.1807256115pmid:30404913
[9]	Shaked Y. The pro-tumorigenic host response to cancer therapies[J]. Nat Rev Cancer, 2019,19(12):667-685. DOI: 10.1038/s41568-019-0209-6. doi:10.1038/s41568-019-0209-6pmid:31645711
[10]	Kuczynski EA, Vermeulen PB, Pezzella F, et al. Vessel co-option in cancer[J]. Nat Rev Clin Oncol, 2019,16(8):469-493. DOI: 10.1038/s41571-019-0181-9. doi:10.1038/s41571-019-0181-9pmid:30816337
[11]	Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors[J]. Nat Med, 2019,25(10):1488-1499. DOI: 10.1038/s41591-019-0596-y. doi:10.1038/s41591-019-0596-ypmid:31591590
[12]	Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 2018,175(2):313-326. DOI: 10.1016/j.cell.2018.09.035. doi:10.1016/j.cell.2018.09.035pmid:30290139
[13]	Li X, Wenes M, Romero P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy[J]. Nat Rev Clin Oncol, 2019,16(7):425-441. DOI: 10.1038/s41571-019-0203-7. doi:10.1038/s41571-019-0203-7pmid:30914826
[14]	Garrett WS. The gut microbiota and colon cancer[J]. Science, 2019,364(6446):1133-1135. DOI: 10.1126/science.aaw2367. doi:10.1126/science.aaw2367pmid:31221845
[15]	Villanueva MT. Cancer: reset your circadian clock[J]. Nat Rev Drug Discov, 2018,17(3):166. DOI: 10.1038/nrd.2018.24. doi:10.1038/nrd.2018.24pmid:29449708
[16]	Madhusoodanan J. News feature: do hosts and their microbes evolve as a unit?[J]. Proc Natl Acad Sci U S A, 2019,116(29):14391-14394. DOI: 10.1073/pnas.1908139116. doi:10.1073/pnas.1908139116pmid:31311888
[17]	Hohenlohe PA, McCallum HI, Jones ME, et al. Conserving adaptive potential: lessons from Tasmanian devils and their transmissible cancer[J]. Conserv Genet, 2019,20(1):81-87. DOI: 10.1007/s10592-019-01157-5. doi:10.1007/s10592-019-01157-5pmid:31551664
[18]	Archetti M, Pienta KJ. Cooperation among cancer cells: applying game theory to cancer[J]. Nat Rev Cancer, 2019,19(2):110-117. DOI: 10.1038/s41568-018-0083-7. doi:10.1038/s41568-018-0083-7pmid:30470829
[19]	Karlsson J, Valind A, Holmquist Mengelbier L, et al. Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer[J]. Nat Genet, 2018,50(7):944-950. DOI: 10.1038/s41588-018-0131-y. doi:10.1038/s41588-018-0131-ypmid:29867221
[20]	Kaznatcheev A, Peacock J, Basanta D, et al. Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer[J]. Nat Ecol Evol, 2019,3(3):450-456. DOI: 10.1038/s41559-018-0768-z. doi:10.1038/s41559-018-0768-zpmid:30778184
[21]	Madan E, Pelham CJ, Nagane M, et al. Flower isoforms promote competitive growth in cancer[J]. Nature, 2019,572(7768):260-264. DOI: 10.1038/s41586-019-1429-3. doi:10.1038/s41586-019-1429-3pmid:31341286
[22]	Janiszewska M, Tabassum DP, Castaño Z, et al. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments [J]. Nat Cell Biol, 2019,21(7):879-888. DOI: 10.1038/s41556-019-0346-x. doi:10.1038/s41556-019-0346-xpmid:31263265
[23]	Tonnessen-Murray CA, Frey WD, Rao SG, et al. Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival[J]. J Cell Biol, 2019,218(11):3827-3844. DOI: 10.1083/jcb.201904051. doi:10.1083/jcb.201904051pmid:31530580
[24]	Frampton D, Schwenzer H, Marino G, et al. Molecular signatures of regression of the canine transmissible venereal tumor[J]. Cancer Cell, 2018, 33(4):620-633.e6. DOI: 10.1016/j.ccell.2018.03.003. doi:10.1016/j.ccell.2018.03.003pmid:29634949
[25]	Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution[J]. Nature, 2019,567(7749):479-485. DOI: 10.1038/s41586-019-1032-7. doi:10.1038/s41586-019-1032-7pmid:30894752
[26]	Angelova M, Mlecnik B, Vasaturo A, et al. Evolution of metastases in space and time under immune selection[J]. Cell, 2018,175(3):751-765.e16. DOI: 10.1016/j.cell.2018.09.018. doi:10.1016/j.cell.2018.09.018pmid:30318143
[27]	Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab[J]. Cell, 2017,171(4):934-949.e16. DOI: 10.1016/j.cell.2017.09.028. doi:10.1016/j.cell.2017.09.028pmid:29033130
[28]	Woolston A, Khan K, Spain G, et al. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR Treatment in colorectal cancer[J]. Cancer Cell, 2019,36(1):35-50.e9. DOI: 10.1016/j.ccell.2019.05.013. doi:10.1016/j.ccell.2019.05.013pmid:31287991
[29]	Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy[J]. Nat Rev Drug Discov, 2020,19(1):39-56. DOI: 10.1038/s41573-019-0044-1. doi:10.1038/s41573-019-0044-1pmid:31601994
[30]	Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy[J]. Nature, 2019,574(7776):45-56. DOI: 10.1038/s41586-019-1593-5. doi:10.1038/s41586-019-1593-5pmid:31578484
[31]	Matyunina EA, Emelyanov AV, Kurbatova TV, et al. Evolutionarily novel genes are expressed in transgenic fish tumors and their orthologs are involved in development of progressive traits in humans[J]. Infect Agent Cancer, 2019,14:46. DOI: 10.1186/s13027-019-0262-5. doi:10.1186/s13027-019-0262-5pmid:31827597
[32]	Makashov AA, Malov SV, Kozlov AP. Oncogenes, tumor suppressor and differentiation genes represent the oldest human geneclasses and evolve concurrently[J]. Sci Rep, 2019,9(1):16410. DOI: 10.1038/s41598-019-52835-w. doi:10.1038/s41598-019-52835-wpmid:31712655
[33]	Auslander N, Wolf YI, Koonin EV. In silico learning of tumor evolution through mutational time series[J]. Proc Natl Acad Sci U S A, 2019,116(19):9501-9510. DOI: 10.1073/pnas.1901695116. pmid:31015295
[34]	Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities[J]. Nat Rev Cancer, 2019,19(2):97-109. DOI: 10.1038/s41568-018-0095-3. doi:10.1038/s41568-018-0095-3pmid:30578414
[35]	Montefiori LE, Nobrega MA. Gene therapy for pathologic gene expression[J]. Science, 2019,363(6424):231-232. DOI: 10.1126/science.aaw0635. doi:10.1126/science.aaw0635pmid:30655431
[36]	Porteus MH. A new class of medicines through DNA editing[J]. N Engl J Med, 2019,380(10):947-959. DOI: 10.1056/NEJMra1800729. doi:10.1056/NEJMra1800729pmid:30855744
[37]	Miller AM, Shah RH, Pentsova EI, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid[J]. Nature, 2019,565(7741):654-658. DOI: 10.1038/s41586-019-0882-3. doi:10.1038/s41586-019-0882-3pmid:30675060
[38]	Hutson M. Bringing machine learning to the masses[J]. Science, 2019,365(6452):416-417. DOI: 10.1126/science.365.6452.416. doi:10.1126/science.365.6452.416pmid:31371586
[39]	Eraslan G Avsec Gagneur J, et al. Deep learning: new computational modelling techniques for genomics[J]. Nat Rev Genet, 2019,20(7):389-403. DOI: 10.1038/s41576-019-0122-6. doi:10.1038/s41576-019-0122-6pmid:30971806

Adaptive therapy of human cancers: targeting cancer evolution

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References39

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.